Publications by authors named "Patricia Balieiro"
Effective radical cure of Plasmodium vivax malaria is essential for malaria elimination in Brazil. P. vivax radical cure requires administration of a schizonticide, such as chloroquine, plus an 8-aminoquinoline.
View Article and Find Full Text PDFOperational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
Lancet Infect Dis
June 2024
Background: Prevention of Plasmodium vivax malaria recurrence is essential for malaria elimination in Brazil. We evaluated the real-world effectiveness of an updated treatment algorithm for P vivax radical cure in the Brazilian Amazon.
Methods: In this non-interventional observational study, we used retrospective data from the implementation of a P vivax treatment algorithm at 43 health facilities in Manaus and Porto Velho, Brazil.
Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
Lancet Glob Health
March 2024
Background: To achieve malaria elimination, Brazil must implement Plasmodium vivax radical cure. We aimed to investigate the operational feasibility of point-of-care, quantitative, glucose-6-phosphate dehydrogenase (G6PD) testing followed by chloroquine plus tafenoquine or primaquine.
Methods: This non-interventional, observational study was done at 43 health facilities in Manaus (Amazonas State) and Porto Velho (Rondônia State), Brazil, implementing a new P vivax treatment algorithm incorporating point-of-care quantitative G6PD testing to identify G6PD status and single-dose tafenoquine (G6PD normal, aged ≥16 years, and not pregnant or breastfeeding) or primaquine (intermediate or normal G6PD, aged ≥6 months, not pregnant, or breastfeeding >1 month).
Prevalence of glucose 6-phosphate dehydrogenase deficiency in highly malaria-endemic municipalities in the Brazilian Amazon: A region-wide screening study.
Lancet Reg Health Am
August 2022
Article Synopsis
- Difficulties in assessing glucose-6-phosphate dehydrogenase deficiency (G6PDd) in remote areas pose risks for safely using malaria treatments like primaquine and tafenoquine, due to potential hemolysis.
- A study conducted in the Brazilian Amazon from 2014 to 2018 screened nearly 15,000 males for G6PDd, revealing a 5.6% prevalence overall, with the highest rates in Acre and Amapá.
- The findings suggest that many individuals could suffer hemolysis if treated with certain anti-malarial drugs, highlighting the need for G6PDd screening to protect patients and support malaria elimination efforts.
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not routinely performed before primaquine treatment in most endemic areas, despite the risk of primaquine-associated hemolysis. This is due to the operational challenges associated with pragmatic G6PD testing and as such needs to be addressed.
Methods And Findings: This mixed-methods operational study was aimed at implementing the quantitative point-of-care Standard G6PD (SD Biosensor, Korea) screening test in malaria treatment units (MTUs) in the municipalities of Rio Preto da Eva and Mâncio Lima, in the Brazilian Amazon, between mid-January 2020 and December 2020.
Background: Although primaquine (PQ) is indicated for G6PD-deficient patients, data on weekly PQ use in Brazil are limited.
Methods: We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020.
Results: Patients receiving weekly PQ treatment had a lower risk of recurrence than those receiving daily PQ treatment (risk ratio: 0.
Background: As quantitative glucose 6-phosphate dehydrogenase deficiency (G6PDd) screening tools are evaluated in operational studies, questions remain as to whether they are cost-effective. Here, a cost-effectiveness analysis (CEA) was performed to estimate the Incremental Cost-effectiveness Ratio (ICER) of the introduction of quantitative screening test to detect G6PDd among P. vivax carriers in two municipalities in the Brazilian Amazon.
View Article and Find Full Text PDFCorrection: Social, demographic, health care and co-morbidity predictors of tuberculosis mortality in Amazonas, Brazil: a multiple cause of death approach.
PLoS One
February 2020
[This corrects the article DOI: 10.1371/journal.pone.
View Article and Find Full Text PDFSocial, demographic, health care and co-morbidity predictors of tuberculosis mortality in Amazonas, Brazil: a multiple cause of death approach.
PLoS One
April 2020
Article Synopsis
- The study aimed to estimate tuberculosis (TB) mortality rates and analyze death certificates in Amazonas, Brazil, from 2006-2014, focusing on TB's role as an underlying or associated cause of death.
- The analysis categorized death records into three groups: TB not reported (TBNoR), TB as underlying cause (TBUC), and TB as an associated cause (TBAC), using statistical methods to estimate mortality rates and identify predictors.
- The findings revealed that TBUC was linked to socioeconomic factors and healthcare access, while TBAC was associated with age groups that experience high rates of HIV incidence.
Factors associated with unspecified and ill-defined causes of death in the State of Amazonas, Brazil, from 2006 to 2012.
Cien Saude Colet
January 2020
This study aimed to investigate factors associated with unspecified and ill-defined causes of death in the State of Amazonas (AM), Brazil. This is a cross-sectional study on 90,439 non-fetal deaths of residents in AM from 2006 to 2012. The hierarchical multinomial logistic model estimated odds ratios of unspecified and ill-defined causes of death.
View Article and Find Full Text PDF